Advanced search
Add to list

Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up

(2005) BLOOD. 106(11).
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
SOLAL-CELIGNY, P, K IMRIE, A BELCH, et al. “Mabthera (Rituximab) Plus CVP Chemotherapy for First-line Treatment of Stage III/IV Follicular non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-up.” Blood. Vol. 106. AMER SOC HEMATOLOGY, 2005. 106. Print.
APA
SOLAL-CELIGNY, P., IMRIE, K., BELCH, A., ROBINSON, K., CUNNINGHAM, D., RUEDA, A., CATALANO, J., et al. (2005). Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma (NHL): Confirmed efficacy with longer follow-up. BLOOD (Vol. 106, p. 106). AMER SOC HEMATOLOGY.
Chicago author-date
SOLAL-CELIGNY, P, K IMRIE, A BELCH, KS ROBINSON, D CUNNINGHAM, A RUEDA, J CATALANO, et al. 2005. “Mabthera (Rituximab) Plus CVP Chemotherapy for First-line Treatment of Stage III/IV Follicular non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-up.” In Blood, 106:106. AMER SOC HEMATOLOGY.
Chicago author-date (all authors)
SOLAL-CELIGNY, P, K IMRIE, A BELCH, KS ROBINSON, D CUNNINGHAM, A RUEDA, J CATALANO, Fritz Offner, J WALEWSKI, J RAPOSO, P SMITH, and R MARCUS. 2005. “Mabthera (Rituximab) Plus CVP Chemotherapy for First-line Treatment of Stage III/IV Follicular non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-up.” In Blood, 106:106. AMER SOC HEMATOLOGY.
Vancouver
1.
SOLAL-CELIGNY P, IMRIE K, BELCH A, ROBINSON K, CUNNINGHAM D, RUEDA A, et al. Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma (NHL): Confirmed efficacy with longer follow-up. BLOOD. AMER SOC HEMATOLOGY; 2005. p. 106.
IEEE
[1]
P. SOLAL-CELIGNY et al., “Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma (NHL): Confirmed efficacy with longer follow-up,” in BLOOD, 2005, vol. 106, no. 11, p. 106.
@inproceedings{350728,
  author       = {SOLAL-CELIGNY, P and IMRIE, K and BELCH, A and ROBINSON, KS and CUNNINGHAM, D and RUEDA, A and CATALANO, J and Offner, Fritz and WALEWSKI, J and RAPOSO, J and SMITH, P and MARCUS, R},
  booktitle    = {BLOOD},
  issn         = {0006-4971},
  language     = {eng},
  number       = {11},
  pages        = {106A-106A},
  publisher    = {AMER SOC HEMATOLOGY},
  title        = {Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up},
  volume       = {106},
  year         = {2005},
}

Web of Science
Times cited: